Prostatype Genomics reaches important commercial breakthrough by initiating billing for Prostatype® to insurance companies in the USA

About this update from Medicare Group Qsc

Prostatype Genomics AB (“Prostatype Genomics” or the “Company”) has reached an important commercial milestone in the USA by immediately starting to bill Prostatype® to several insurance companies. Prostatype® has since Q2 2024 been in clinical use among several leading urologists in the USA to build clinical experience of the product and since the American insurance market for patients consists of hundreds of insurance companies of varying sizes, Prostatype Genomics’ revenues in the USA will not come from just one single insurer. Prostatype Genomics can today announce that the Company has reached an important commercial milestone in the USA by immediately starting to bill Prostatype® to several insurance companies.The work to build clinical experience of Prostatype® among urologists in the USA is a work that has been – and is – ongoing in parallel with the Company’s reimbursement application to the single largest insurer in the USA, Medicare. The Company continues to maintain a constructive dialogue with Medicare regarding its reimbursement application, whereby the Company continuously receives questions from Medicare regarding Prostatype®, which are also continuously answered. As previously communicated, the Company expects to obtain reimbursement approval from Medicare within the calendar year 2025 which would then also trigger the billing for Medicare-covered patients.Fredrik Rickman, CEO of Prostatype Genomics, comments:“We are following the plan and process previously communicated regarding the importance of step by step building presence and commercial infrastructure for Prostatype® in USA. Ensuring that selected leading urologists have had the opportunity to evaluate Prostatype® and build their clinical experience is a decisive step in the commercial process, and we have now reached the point where Prostatype® is in routine clinical use in several locations. The experiences of Prostatype® in the USA continue to be positive, which of course is a fundamental prerequisite for moving forward. We have now reached this next step in our commercial process and are starting to bill several of the private insurance companies connected to patients already tested for, as well as future patients diagnosed with prostate cancer. Naturally, we have worked on these processes in parallel with our Medicare application, which is still ongoing and which reimbursement a...

View stock analysis, news, and events for Medicare Group Qsc